Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin
- 1 January 1990
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 14 (2), 161-167
- https://doi.org/10.1016/0145-2126(90)90045-b
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Disappearance of Trisomy 8 after Alpha-2 Interferon in a Patient with Myelodysplastic SyndromeNew England Journal of Medicine, 1988
- Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic SyndromesNew England Journal of Medicine, 1987
- Successful oral chemotherapy with idarubicin in refractory anaemia with excess blastsEuropean Journal of Haematology, 1987
- EFFECT OF 13-cis-RETINOIC ACID ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROMEThe Lancet, 1987
- Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 casesBritish Journal of Haematology, 1987
- The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromesBritish Journal of Haematology, 1986
- VERY-LOW-DOSE CYTARABINE FOR MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA IN THE ELDERLYThe Lancet, 1986
- Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose CytarabineNew England Journal of Medicine, 1983
- A phase II study of aclacinomycin A in acute leukemia in adultsCancer Treatment Reviews, 1980
- DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPYBritish Journal of Haematology, 1979